Jim Simons Rhythm Pharmaceuticals, Inc. Transaction History

Renaissance Technologies LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$3.12 - $12.25 $72,072 - $282,975	-23,100 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$6.13 - $12.24 $141,603 - $282,744	23,100 New	23,100 $266,000
Q3 2021 Nov 12, 2021	SELL	$11.68 - $20.72 $609,696 - $1.08 Million	-52,200 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$18.52 - $22.55 $59,264 - $72,160	3,200 Added 6.53%	52,200 $1.02 Million
Q1 2021 May 13, 2021	BUY	$20.25 - $39.49 $789,750 - $1.54 Million	39,000 Added 390.0%	49,000 $1.04 Million
Q4 2020 Feb 10, 2021	SELL	$21.17 - $32.61 $3.96 Million - $6.1 Million	-187,000 Reduced 94.92%	10,000 $297,000
Q3 2020 Nov 13, 2020	SELL	$18.13 - $30.61 $705,257 - $1.19 Million	-38,900 Reduced 16.49%	197,000 $4.27 Million
Q2 2020 Aug 13, 2020	BUY	$14.41 - $25.35 $2.03 Million - $3.58 Million	141,200 Added 149.1%	235,900 $5.26 Million
Q1 2020 May 14, 2020	BUY	$13.16 - $22.9 $645,537 - $1.12 Million	49,053 Added 107.46%	94,700 $1.44 Million
Q4 2019 Feb 13, 2020	BUY	$19.53 - $25.5 $682,514 - $891,148	34,947 Added 326.61%	45,647 $1.05 Million
Q3 2019 Nov 13, 2019	BUY	$18.62 - $24.51 $199,234 - $262,257	10,700 New	10,700 $231,000

192

67.3M

834K

78.6K

Ticker RYTM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,720,000
Market Cap $3.34B
Description
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convert...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.